Peptide Profile
Thymulin Analog (PAT)
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
Dose Range
1 mcg-50 mcgmcg
Frequency
Once daily
Route
Intraperitoneal injection
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Strong
Compound Profile
Scientific & Efficacy Data
C37H62N12O15
Molecular Formula
858.9 Da
Molecular Weight
Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose
Half-Life
Effective via intraperitoneal and intracerebroventricular routes in preclinical models
Bioavailability
Not assigned
CAS #
Not available
PubChem Status
Developed By · 2006
Multiple independent researchers (polypharmacy peptide)
Various research institutions and cosmetic companies
Primary Benefits
Demonstrates analgesic potency comparable to or exceeding morphine and NSAIDs in multiple preclinical pain models including CCI and SNI neuropathy
Potent inhibitor of NF-κB signaling and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, NGF) through alpha-7 nicotinic receptor potentiation
Reduces cerebral neuroinflammation and cytokine upregulation following immune challenge, suggesting potential neuroprotective applications
Amino Acid Sequence
pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (nonapeptide)Dosing
How much
do I take?
Timing
Best time to take
Administer Thymulin Analog (PAT) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Thymulin Analog (PAT) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Thymulin Analog (PAT) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Neuropathic pain research
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Novel analgesic mechanism investigation
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated pain pathway studies
Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Not approved for human use
- ×Potential immune modulation concerns with chronic use
- ×Unknown drug-drug interactions
- ×Pregnancy and lactation (insufficient safety data)
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Thymulin Analog (PAT) use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Thymulin Analog (PAT) vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Thymulin Analog (PAT) evidence comes entirely from preclinical animal studies published in peer-reviewed journals over 17+ years of investigation. No Phase 1 human clinical trials have been completed. All safety and efficacy data is extrapolated from rodent models studying immune modulation via alpha-7 nicotinic acetylcholine receptor activity.
Common Side Effects
Experienced by some users
Injection Site Reaction
Theoretical local reaction at intraperitoneal injection site; not specifically documented as adverse in published studies
Management: Rotate injection sites; standard aseptic technique
Transient Immune Modulation
As an immune-modulating peptide, PAT may transiently alter cytokine profiles beyond the target inflammatory site
Management: Monitor cytokine levels in research settings; effects expected to be reversible upon discontinuation
Mild Sedation
Theoretical central nervous system effect at high doses given cholinergic pathway involvement; not observed at standard research doses
Management: Dose adjustment if behavioral changes noted in animal models
Short Duration of Action
Single-dose effects diminish by 3-4 hours post-administration, requiring repeated dosing for sustained relief
Management: Daily dosing protocols show progressive improvement; extended-release formulations not yet developed
Less Common
- •Potential Immune Suppression
- •CNS Effects with Central Administration
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Thymulin Analog (PAT)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Combining with receptor-specific agonists and antagonists elucidates PAT mechanism of action through cholinergic pathways
- ✓Monitoring IL-1β, IL-6, TNF-α, and NGF levels validates anti-inflammatory efficacy in research models
- ✓CCI and SNI models provide validated platforms for assessing PAT analgesic potency
With medications
- !Strong Immunosuppressants - May compound immune suppression through overlapping anti-inflammatory mechanisms
- !Nicotinic Receptor Antagonists - Alpha-7 nAChR antagonists like methyllycaconitine block PAT primary mechanism of action
- !High-Dose Corticosteroids - Redundant anti-inflammatory pathways may confound research outcomes or cause excessive immune suppression
With supplements
- ✓Multivitamins - Generally safe to take alongside Thymulin Analog (PAT). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Strong human trials
What to Expect
Acute Effects (1-4 Hours)
What you might notice
- •Peak analgesic and anti-inflammatory effects at 1-2 hours post-injection;
- •significant reduction in mechanical allodynia and thermal hyperalgesia
What's normal
- •Initial response to Thymulin Analog (PAT) is beginning at the cellular level
- •Different individuals experience Thymulin Analog (PAT)'s onset at different rates
- •Transient systemic effects from initial Thymulin Analog (PAT) exposure are common
What's next
- →Maintain consistent Thymulin Analog (PAT) administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Repeated Dosing (Days to Weeks)
What you might notice
- •Progressive improvement in pain outcomes with daily administration;
- •cumulative anti-inflammatory effects observed in neuropathic pain models
What's normal
- •Thymulin Analog (PAT) is achieving sufficient receptor engagement
- •Initial mechanism of Thymulin Analog (PAT) is taking effect
- •Early transient effects from Thymulin Analog (PAT) administration are resolving
What's next
- →Maintain consistent Thymulin Analog (PAT) administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Research Endpoint (2-4 Weeks)
What you might notice
- •Maximum therapeutic effects achieved in chronic neuropathic pain models;
- •sustained cytokine suppression and neuroinflammation reduction
What's normal
- •Full therapeutic effects of Thymulin Analog (PAT) are well-characterized at this point
- •Maintenance of Thymulin Analog (PAT)'s therapeutic effects is typical
- •Tolerance patterns with Thymulin Analog (PAT) are generally stable over months
What's next
- →Comprehensive assessment of Thymulin Analog (PAT) efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Thymulin Analog (PAT) over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Targeting inflammatory components in neuropathic pain: The analgesic effect of thymulin related peptide"
Research investigators, 2019
Finding: Thymulin-related peptides target inflammatory components in neuropathic pain by reducing cytokine-mediated neuroinflammation. These peptides regulate inflammatory mediators for novel therapeutic approaches to chronic pain.
View Study"Involvement of alpha-7 nicotinic acetylcholine receptors in the anti-inflammatory action of PAT"
Research investigators, 2013
Finding: PAT demonstrated anti-inflammatory action through potentiation of alpha-7 nicotinic acetylcholine receptors, reversing inflammatory nociceptive hyperactivity in rats. The mechanism differed from traditional analgesics.
View Study"Role of thymulin or its analogue as a new analgesic molecule"
Research investigators, 2006
Finding: No abstract available for comprehensive analysis.
View Study"A thymulin analogue peptide with powerful inhibitory effects on pain of neurogenic origin"
Research investigators, 2003
Finding: Thymulin analog PAT produced powerful neuropathic pain reduction equal to morphine in chronic constriction and spared nerve injury models. Daily treatment progressively attenuated all neuropathic manifestations.
View Study"Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat"
Research investigators, 2002
Finding: PAT significantly reduced inflammatory hyperalgesia in rats through dose-dependent decrease in pro-inflammatory cytokines. Analgesic effects matched dexamethasone and indomethacin.
View StudyFrequently Asked Questions